•Vedolizumab is an appropriate alternative in patients with moderately or severely active localized ileocecal CD who are refractory to steroids and/or anti-TNF therapy (Statements 5C and 5D; evidence level 1)b•Vedolizumab is an appropriate alternative in patients with active colonic CD who are refractory to steroids and/or anti-TNF therapy (Statement 5E; evidence level 1)b•Vedolizumab is appropriate for maintenance treatment in patients who have achieved remission with vedolizumab (Statement 6F; evidence level 1)b. The gene discussed is TNF; the disease is Cowden disease.